Not this nonsense again. Jonny just stop. It's not going to $20 anytime soon and you know it. With six years of work needed to perform the REQUIRED SPA trials and no money to initiate them in the first place $20 isn't going to happen any time soon if at all. Stop being a desperate troll.
Why don't you stop spouting nonsense? There is NO REQUIREMENT to run the SPA trials for HF, unless they want the product label to indicate Gencaro for heart failure.
Much like the uninformed and ignorant Chunks, you do not seem to have kept up with ABIO's evolving strategy. Let me summarize so that you do not have to actually read the latest 10Q.
The company is now pursuing approval for Gencaro for AF (atrial fibrillation for the morons like you and Chunks). They believe they can gain approval (for AF, not HF, in case you're having problems keeping up) via a 2 year, 300 patient study.
If they can negotiate a reasonable SPA for a 300 patient AF trial, that may be the porkchop they need to attract the big dogs.
You can expect a big pop in the price per share if they can get a SPA for an AF trial.
I am aware of the AF focus, but they still need money and/or partner to do it since they lack money. So, you can calm down a-hole. Just because they "believe" they can do something doesn't mean it's going to happen especially when the data is marginal. I'm not against the company, but I'm tired of reading the same old BS about how this stock is going to leap to $20-$40 magically overnight. The change in focus really sounds more like desperation hoping that their failed drug might be usable in some other application. It could happen, but I won't be holding my breath. IF anything I would like to see the load of idiot pumpers start discussing the AF study, but even they are still fixed on the HF aspect of this drug. So, quit being just another douche bag and let's hope a discussion on how this company is going to pull off the AF study without any backers or money to do the study. More facts less bull if you please.